Antiretroviral treatment for HIV infection: Swedish recommendations 2019

Jaran EriksenUnit of Infectious Diseases/Venhälsan, Södersjukhuset, Stockholm, Sweden; ;Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden; Correspondence[email protected]

http://orcid.org/0000-0003-1146-5615

Christina CarlanderDepartment of Infectious Diseases, Västmanland County Hospital, Västerås, Sweden; ;Division of Infectious Diseases, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden;

Jan AlbertDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden; ;Department of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden;

Leo FlamholcDepartment of Infectious Diseases, Skåne University Hospital, Malmö, Sweden;

Magnus GisslénDepartment of Infectious Diseases, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; ;Department of Infectious Diseases, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden;

Lars NavérDivision of Paediatrics, Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet, Stockholm, Sweden; ;Department of Paediatrics, Karolinska University Hospital, Stockholm, Sweden;

Veronica SvedhemDivision of Infectious Diseases, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden; ;Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden;

Aylin YilmazDepartment of Infectious Diseases, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden;

Anders SönnerborgDivision of Infectious Diseases, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden; ;Department of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden; ;Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden; ;Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden

show all

Abstract

The Swedish Reference Group for Antiviral Therapy (RAV) published recommendations for the treatment of HIV infection in this journal most recently in 2017. An expert group under the guidance of RAV here provides updated recommendations. The most important updates in the present guidelines are the following: (a) The risk of HIV transmission through condomless sex from individuals with fully suppressed HIV viral load is effectively zero. (b) Pre-exposure prophylaxis (PrEP) is recommended for groups with a high risk of HIV infection. (c) Since the last update, two new substances have been registered: bictegravir and doravirine. (d) Dual treatment may be an alternative in selected patients, using lamivudine + dolutegravir or lamivudine + boosted darunavir/atazanavir. As with previous publications, recommendations are evidence-graded in accordance with the Oxford Centre for Evidence Based Medicine. This document does not cover treatment of opportunistic infections and tumours.

Keywords:

Disclosure statement

The authors declare that they have no conflicts of interest related to the submitted paper.

Antiretroviral treatment for HIV infection: Swedish recommendations 2019

Information for

Open access

Opportunities

Help and information

Antiretroviral treatment for HIV infection: Swedish recommendations 2019

Abstract

Disclosure statement

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature